In this issue:
Major lipids, apolipoproteins and risk of vascular disease
Use of aldosterone antagonists in HF
A selective endothelin-receptor antagonist for treatment resistant HT
Treatment disparities in patients with diabetes presenting with AMI
The COACH Program pr
Please login below to download this issue (PDF)